28 related articles for article (PubMed ID: 11107151)
1. Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification.
Ikegaki N; Shimada H;
JCO Precis Oncol; 2019; 3():. PubMed ID: 31840131
[No Abstract] [Full Text] [Related]
2. Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.
Srivastava S; Reid BJ; Ghosh S; Kramer BS
J Cell Physiol; 2016 Sep; 231(9):1870-5. PubMed ID: 26505642
[TBL] [Abstract][Full Text] [Related]
3. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
4. Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan.
Suita S; Tajiri T; Higashi M; Tanaka S; Kinoshita Y; Takahashi Y; Tatsuta K
Eur J Pediatr Surg; 2007 Feb; 17(1):23-8. PubMed ID: 17407017
[TBL] [Abstract][Full Text] [Related]
5. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening.
Kusafuka T; Nagahara N; Oue T; Imura K; Nakamura T; Kobayashi Y; Komoto Y; Fukuzawa M; Okada A; Nakayama M
Cancer; 1995 Aug; 76(4):695-9. PubMed ID: 8625168
[TBL] [Abstract][Full Text] [Related]
6. High expression of the novel endothelin-converting enzyme genes, Nbla03145/ECEL1alpha and beta, is associated with favorable prognosis in human neuroblastomas.
Kawamoto T; Ohira M; Hamano S; Hori T; Nakagawara A
Int J Oncol; 2003 Apr; 22(4):815-22. PubMed ID: 12632073
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of N-myc messenger RNA in neuroblastomas found by mass screening.
Matsunaga T; Shirasawa H; Hishiki T; Yoshida H; Kouchi K; Ohtsuka Y; Kawamura K; Etoh T; Ohnuma N
Clin Cancer Res; 2000 Aug; 6(8):3199-204. PubMed ID: 10955804
[TBL] [Abstract][Full Text] [Related]
8. Risk of unfavorable character among neuroblastomas detected through mass screening. The Japanese Infantile Neuroblastoma Cooperative Study.
Tanaka T; Matsumura T; Iehara T; Sawada T
Med Pediatr Oncol; 2000 Dec; 35(6):705-7. PubMed ID: 11107151
[TBL] [Abstract][Full Text] [Related]
9. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathology of human neuroblastomas.
Brodeur GM
Semin Diagn Pathol; 1994 May; 11(2):118-25. PubMed ID: 7809505
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
12. Diversity in neuroblastomas and discrimination of the risk to progress.
Tanaka T; Iehara T; Sugimoto T; Hamasaki M; Teramukai S; Tsuchida Y; Kaneko M; Sawada T
Cancer Lett; 2005 Oct; 228(1-2):267-70. PubMed ID: 15913885
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
